Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxin Shengmai Granules for Stable Angina Pectoris
NCT04270071Phase 4Unknown
- Sponsor
- Guang'anmen Hospital
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in stable angina pectoris comparing Yangxin Shengmai Granules with Placebo (2 arms). Primary endpoint: Stopping or reducing rate of the nitroglycerin tablets at 4 weeks. Status: unknown.
02
Drugs
Yangxin Shengmai
03
Conditions
stable angina pectoris
Beyond the preview
Go deeper on NCT04270071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270071.